Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis

The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries

(2016) Sang Woong Youn et al.   Annals of Dermatology

Treatment Satisfaction of Patients with Psoriasis

(2015) M Schaarschmidt et al.   ACTA DERMATO-VENEREOLOGICA

Comparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report

(2015) Sang Woong Youn et al.   Annals of Dermatology

Efficacy comparison of ustekinumab between anti-tumor necrosis factor-αdrug-naïve and anti-tumor necrosis factor-αdrug-resistant Japanese psoriasis cases

(2015) Naomi Takahashi et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort

(2015) Ignacio García-Doval et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2015) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Cardiovascular risk factors influence response to biological therapies in psoriasis

(2015) Ana Batalla et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities

(2014) Julia Shlyankevich et al.   AMERICAN JOURNAL OF MEDICINE

Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients

(2014) Koichi Yanaba et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

(2014) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

What Happened after the Clinical Trials: Long-Term Safety and Efficacy of Ustekinumab in Daily Clinical Practice

(2014) Marina Talamonti et al.   DERMATOLOGY

Some clinical factors affecting quality of the response to ustekinumab for psoriasis

(2014) Yoshinori Umezawa et al.   JOURNAL OF DERMATOLOGY

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Heterogeneity of Response to Biologic Treatment: Perspective for Psoriasis

(2013) Emily Edson-Heredia et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses

(2013) Michelle A. Lowes et al.   TRENDS IN IMMUNOLOGY

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials

(2011) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Association between Psoriasis and Cardiovascular Risk Factors in Korean Patients

(2010) Woo Jin Choi et al.   Annals of Dermatology

Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions

(2010) Batya B. Davidovici et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

(2010) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris

(2010) A. Clemmensen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The Gap Between Clinical Trials and Clinical Practice: The Use of Pragmatic Clinical Trials to Inform Regulatory Decision Making

(2009) E P Brass   CLINICAL PHARMACOLOGY & THERAPEUTICS

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

(2008) Alexa B. Kimball   ARCHIVES OF DERMATOLOGY

Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis

(2008) Luigi Naldi et al.   DERMATOLOGY

Low-dose etanercept therapy in moderate to severe psoriasis in Korean

(2008) Jung Im NA et al.   JOURNAL OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET